139549-30-7

Upstream product

• 52600-52-9 ethyl 5-cyano-6-hydroxy-2-methyl-pyridine-3-carboxylate 
• 100-39-0 benzyl bromide 
• 64119-42-2 ethyl 6-chloro-5-cyano-2-methylnicotinate 
• 100-51-6 benzyl alcohol 

Downstream Products

• 139549-34-1 2-(benzyloxy)-3-<2-(benzoxazol-2-yl)ethenyl>-6-methylpyridine-5-carboxamide 
• 147440-52-6 trans-2-(benzyloxy)-3-<2-(benzoxazol-2-yl)ethenyl>-5-(methoxymethyl)-6-methylpyridine 
• 139549-35-2 2-(benzyloxy)-3-<2-(benzoxazol-2-yl)ethenyl>-5-cyano-6-methylpyridine 
• 139549-31-8 2-(benzyloxy)-5-(aninocarbonyl)-6-methylnicotinonitrile 
• 139549-33-0 2-(benzyloxy)-5-(aminocarbonyl)-6-methylnicotinaldehyde 
• 147440-60-6 2-(benzyloxy)-5-(hydroxymethyl)-6-methylnicotinaldehyde 

Relevant academic research and scientific papers

EZH2 Inhibitors

The present invention relates to compounds that inhibit EZH2 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 4. 3-[2-(Benzoxazol-2-yl)ethyl]-5-ethyl-6- methylpyridin-2(1H)-one and analogues

A new series of potent specific 2-pyridinone reverse transcriptase (RT) inhibitors was developed based on the preliminary development lead 3- [(phthalimido)ethyl]-5-ethyl-6-methylpyridin-2(1H)-one (3), a non-nucleoside derivative which exhibited weak anti